Plain-English translation of NCT07788118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called 7×19-THEMIS CAR-T cell therapy for people with aggressive B-cell lymphomas that have come back or stopped responding to previous treatments. CAR-T therapy works by taking your own immune cells, enhancing them in the laboratory to recognize and fight your cancer, and then putting them back into your body. This study will look at whether this particular version of the treatment is safe and how well it works.
People whose lymphoma returns or becomes resistant to standard chemotherapy and other treatments have very few good options left. This medication is designed to give patients with hard-to-treat cancers a new way to fight back using their own enhanced immune system.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a single injection of the modified cell therapy on day 0. Before the injection, you will undergo testing to ensure you are healthy enough for treatment and to collect your immune cells for modification. After receiving the treatment, you will have regular clinic visits and blood tests over several months so doctors can monitor how well the therapy is working and watch for any side effects. The trial will follow you for at least 3 months to assess whether your cancer responds to treatment.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
China